Abintus Bio
Abintus Bio is a preclinical stage gene therapy company that engages in the field of in vivo immune cell reprogramming. The company pursues products that modulate immune cells from within their native environment to enhance patient access and patient outcomes. It focuses on the discovery and development of a portfolio of first-in-class, product candidates that are designed to directly reprogram immune cells from within their native environment using proprietary vectors and related technologies.
Industries
Nr. of Employees
small (1-50)
Abintus Bio
Products
Highly Selective Gene Expression Targeting
This program focuses on targeting specific cell types or states using synthetic biology for gene expression, applicable across various gene delivery systems and therapeutic areas such as leukemia, solid tumors, autoimmune, infectious, and genetic diseases.
Simultaneous Engineering of Immune Cells
This program involves engineering a diverse range of active innate and adaptive immune cells for applications in diseases like lymphoma and solid tumors.
Highly Selective Gene Expression Targeting
This program focuses on targeting specific cell types or states using synthetic biology for gene expression, applicable across various gene delivery systems and therapeutic areas such as leukemia, solid tumors, autoimmune, infectious, and genetic diseases.
Simultaneous Engineering of Immune Cells
This program involves engineering a diverse range of active innate and adaptive immune cells for applications in diseases like lymphoma and solid tumors.